NasdaqGS:PODD

Stock Analysis Report

Executive Summary

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Snowflake

Fundamentals

High growth potential with questionable track record.


Similar Companies

Share Price & News

How has Insulet's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.8%

NasdaqGS:PODD

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

34.1%

NasdaqGS:PODD

9.1%

US Medical Equipment

2.0%

US Market

PODD outperformed the Medical Equipment industry which returned 8.7% over the past year.

PODD outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

PODDIndustryMarket
7 Day-8.8%-0.9%1.3%
30 Day-4.7%0.7%3.9%
90 Day23.0%4.4%3.4%
1 Year34.1%34.1%10.0%9.1%4.2%2.0%
3 Year237.2%237.2%70.7%65.5%47.2%37.6%
5 Year286.2%286.2%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Insulet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Insulet undervalued based on future cash flows and its price relative to the stock market?

490.34x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Insulet's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Insulet's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Insulet is overvalued based on earnings compared to the US Medical Equipment industry average.

Insulet is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Insulet is poor value based on expected growth next year.


Price Based on Value of Assets

Insulet is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Insulet expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

49.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Insulet's revenue is expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).

Insulet's earnings are expected to grow significantly at over 20% yearly.

Insulet's revenue growth is expected to exceed the United States of America market average.

Insulet's earnings growth is expected to exceed the United States of America market average.

Insulet's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Insulet is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Insulet performed over the past 5 years?

38.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Insulet has delivered over 20% year on year earnings growth in the past 5 years.

Insulet has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Insulet has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Insulet has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Insulet used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Insulet has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Insulet's financial position?


Financial Position Analysis

Insulet is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Insulet's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Insulet's level of debt (243.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (249.5% vs 243.2% today).

Debt is not well covered by operating cash flow (11%, less than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 2.4x annual interest expense, ideally 3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.8x debt.


Next Steps

Dividend

What is Insulet's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Insulet's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Insulet's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Insulet has not reported any payouts.

Unable to verify if Insulet's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Insulet has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Insulet's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Insulet's salary, the management and board of directors tenure and is there insider trading?

0.7yrs

Average management tenure


CEO

Shacey Petrovic (45yo)

0.7yrs

Tenure

US$3,664,805

Compensation

Ms. Shacey Petrovic serves as Director of Alydia Health, Inc. She is the President of Insulet Corporation since October, 2016 and its Director since September 10, 2018. She served as Chief Operating Office ...


CEO Compensation Analysis

Shacey's remuneration is lower than average for companies of similar size in United States of America.

Shacey's compensation has increased in line with Insulet recently becoming profitable.


Management Age and Tenure

0.7yrs

Average Tenure

49yo

Average Age

The average tenure for the Insulet management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

59.5yo

Average Age

The tenure for the Insulet board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$408,65217 May 19
Charles Alpuche
EntityIndividual
Role
Chief Operating Officer
Executive VP & COO
Shares3,900
Max PriceUS$104.78
SellUS$153,11906 Mar 19
Aiman Abdel-Malek
EntityIndividual
Shares1,608
Max PriceUS$95.22
SellUS$52,89606 Mar 19
David Lemoine
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares561
Max PriceUS$94.29

Ownership Breakdown


Management Team

  • Pat Sullivan (67yo)

    Consultant

    • Tenure: 0.7yrs
    • Compensation: US$10.35m
  • Jack Kapples (59yo)

    Senior VP

    • Tenure: 0.5yrs
  • Wayde McMillan (49yo)

    Executive VP

    • Tenure: 0.5yrs
  • Deborah Gordon

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 4.7yrs
  • Shacey Petrovic (45yo)

    President

    • Tenure: 0.7yrs
    • Compensation: US$3.66m
  • Phil Hildale

    Senior Vice President of Sales & Customer Care

    • Tenure: 4.7yrs
  • Mike Levitz (45yo)

    • Tenure: 0.5yrs
    • Compensation: US$1.43m
  • Charles Alpuche (59yo)

    Executive VP & COO

    • Tenure: 0.7yrs
    • Compensation: US$2.62m
  • Bret Christensen (47yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.3yrs
    • Compensation: US$1.69m
  • Lauren Budden

    VP, Chief Accounting Officer & Controller

    • Tenure: 0.4yrs

Board Members

  • Sally Crawford (65yo)

    Independent Director

    • Tenure: 10.9yrs
    • Compensation: US$254.33k
  • Tim Scannell (54yo)

    Chairman

    • Tenure: 0.7yrs
    • Compensation: US$252.73k
  • Robert Sherwin

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Howard Wolpert

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Margaret Lawlor

    Member of Educator Advisory Board

    • Tenure: 0yrs
  • Camille Izlar

    Member of Educator Advisory Board

    • Tenure: 0yrs
  • John Fallon (71yo)

    Independent Director

    • Tenure: 6.9yrs
    • Compensation: US$250.39k
  • David Lemoine (71yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$270.12k
  • Shacey Petrovic (45yo)

    President

    • Tenure: 0.7yrs
    • Compensation: US$3.66m
  • Jessica Hopfield (54yo)

    Lead Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$299.89k

Company Information

Insulet Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Insulet Corporation
  • Ticker: PODD
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$8.799b
  • Shares outstanding: 61.43m
  • Website: https://www.insulet.com

Number of Employees


Location

  • Insulet Corporation
  • 100 Nagog Park
  • Acton
  • Massachusetts
  • 1720
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PODDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2007
GOVDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2007

Biography

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tube ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:58
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.